Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries-Reference-Cited by-同舟云学术

Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries

Published:2022-11-01 Issue:11 Volume:26 Page:1023-1032
ISSN:1027-3719
Container-title:The International Journal of Tuberculosis and Lung Disease
language:en
Short-container-title:int j tuberc lung dis

Author:

Stolbrink M.¹,Chinouya M. J.²,Jayasooriya S.³,Nightingale R.⁴,Evans-Hill L.⁵,Allan K.⁶,Allen H.⁷,Balen J.⁸,Beacon T.⁹,Bissell K.¹⁰,Chakaya J.¹¹,Chiang C-Y.¹²,Cohen M.¹³,Devereux G.¹⁴,El Sony A.¹⁵,Halpin D. M. G.¹⁶,Hurst J. R.¹⁷,Kiprop C.¹⁸,Lawson A.¹⁹,Macé C.²⁰,Makhanu A.¹⁸,Makokha P.¹⁸,Masekela R.²¹,Meme H.²²,Khoo E. M.²³,Nantanda R.²⁴,Pasternak S.²⁵,Perrin C.²⁰,Reddel H.²⁶,Rylance S.²⁷,Schweikert P.¹⁹,Were C.²⁵,Williams S.²⁸,Winders T.²⁹,Yorgancioglu A.³⁰,Marks G. B.³¹,Mortimer K.³²

Affiliation:

1. Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK, Stellenbosch University, Tygerberg, South Africa

2. Education Department, Liverpool School of Tropical Medicine, Liverpool, UK

3. Academic Unit of Primary Care, University of Sheffield, Sheffield, UK

4. Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK, IcFEM Dreamland Mission Hospital, Kimilili, Kenya

5. Nifty Fox Creative, Sheffield, UK

6. Healthcare Consultant, Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, The Gambia

7. Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, The Gambia

8. School of Health and Related Research, University of Sheffield, Sheffield, UK

9. Medical Aid International, Bedford, UK

10. School of Population Health, University of Auckland, Auckland, New Zealand

11. Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK, Department of Medicine, Therapeutics and Dermatology, Kenyatta University, Nairobi, Kenya

12. International Union Against Tuberculosis and Lung Disease, Paris, France, Division of Pulmonary Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan, Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

13. Asociación Latinoamericana del Tórax, Forum of International Respiratory Societies, Guatemala

14. Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK

15. The Epidemiological Laboratory (Epi-Lab) for Public Health, Research and Development, Khartoum Sudan

16. University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK

17. UCL Respiratory, University College London, London, UK

18. IcFEM Dreamland Mission Hospital, Kimilili, Kenya

19. AstraZeneca, Cambridge, UK

20. International Union Against Tuberculosis and Lung Disease, Paris, France

21. Department of Paediatrics and Child Health, School of Clinical Medicine, University of KwaZulu Natal, Durban, South Africa

22. Centre for Respiratory Diseases Research, Kenya Medical Research Institute, Nairobi, Kenya

23. Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, International Primary Care Respiratory Group, Larbert, Scotland, UK

24. Makerere University Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda

25. GlaxoSmithKline, Brentford, UK

26. The Woolcock Institute of Medical Research, The University of Sydney, Sydney, NSW, Australia, Global Initiative for Asthma (GINA), Fontana, WI, USA

27. Noncommunicable Diseases Department, World Health Organization, Geneva, Switzerland

28. International Primary Care Respiratory Group, Larbert, Scotland, UK

29. Global Allergy & Airways Patient Platform, Vienna, Austria

30. Department of Pulmonology, Celal Bayar University Medical Faculty, Manisa, Turkey, Global Alliance Against Chronic Respiratory Diseases, Geneva, Switzerland

31. International Union Against Tuberculosis and Lung Disease, Paris, France, University of New South Wales, Sydney, NSW, Australia

32. International Union Against Tuberculosis and Lung Disease, Paris, France, University of Cambridge, Cambridge, UK

Abstract

BACKGROUND: Access to affordable inhaled medicines for chronic respiratory diseases (CRDs) is severely limited in low- and middle-income countries (LMICs), causing avoidable morbidity and mortality. The International Union Against Tuberculosis and Lung Disease convened a stakeholder meeting on this topic in February 2022.METHODS: Focused group discussions were informed by literature and presentations summarising experiences of obtaining inhaled medicines in LMICs. The virtual meeting was moderated using a topic guide around barriers and solutions to improve access. The thematic framework approach was used for analysis.RESULTS: A total of 58 key stakeholders, including patients, healthcare practitioners, members of national and international organisations, industry and WHO representatives attended the meeting. There were 20 pre-meeting material submissions. The main barriers identified were 1) low awareness of CRDs; 2) limited data on CRD burden and treatments in LMICs; 3) ineffective procurement and distribution networks; and 4) poor communication of the needs of people with CRDs. Solutions discussed were 1) generation of data to inform policy and practice; 2) capacity building; 3) improved procurement mechanisms; 4) strengthened advocacy practices; and 5) a World Health Assembly Resolution.CONCLUSION: There are opportunities to achieve improved access to affordable, quality-assured inhaled medicines in LMICs through coordinated, multi-stakeholder, collaborative efforts.

Publisher

International Union Against Tuberculosis and Lung Disease

Subject

Infectious Diseases,Pulmonary and Respiratory Medicine

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Living with Asthma in Low- and Middle-Income Countries in the Six WHO Regions;NEJM Evidence;2024-01

2. Decline of the chronic respiratory disease mortality in the WHO Western Pacific Region;Journal of Thoracic Disease;2023-10

3. “Asthma is a very bully disease” – patient experiences of living with chronic respiratory diseases in Cape Town, South Africa;International Journal for Equity in Health;2023-09-14

4. Global initiative for asthma: 30 years of promoting evidence‐based asthma care;Allergy;2023-06-30

5. GOLD 2023 Executive Summary: responses from the GOLD Scientific Committee;European Respiratory Journal;2023-06